Suppr超能文献

识别稳定表位的抗独特型抗体限制了小鼠B细胞淋巴瘤中独特型变体的出现。

Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma.

作者信息

Weiner G J, Kaminski M S

机构信息

Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109.

出版信息

J Immunol. 1990 Mar 15;144(6):2436-45.

PMID:1690244
Abstract

The emergence of Id variants is a major escape mechanism from anti-Id therapy of human B cell malignancies and of the murine B cell lymphoma 38C13. To determine what impact the epitope specificity of anti-Id antibodies has on the prevention of emergence of such Id variants in the 38C13 lymphoma, anti-Id mAb of varying epitope specificity for the Id of 38C13 tumor cells were produced and studied. Some antibodies, produced by immunizing mice with both the wild-type 38C13 IgM and variant IgM, cross-reacted with wild-type 38C13 IgM and with all four members of a panel of variant IgM. These anti-Id did not react with separated 38C13 IgM H or L chains by Western blot, but did react with the cytoplasmic H chain of the surface Ig- variant cell line T2D that expresses the same H chain as wild-type 38C13 in its cytoplasm but does not express any associated L chain. In contrast, anti-Id of narrower specificity did not react with this H chain. This indicated that the broadly cross-reactive antibodies recognized a stable epitope on 38C13 H chain. When a broadly cross-reactive antibody MS11G6 was compared to S1C5, an antibody of narrower specificity, MS11G6, was superior at preventing tumor growth in mice inoculated with 38C13 cells. Moreover, no surface Ig+ variants emerged in escaping tumors in the MS11G6-treated group, whereas such variants were common in the S1C5 treated group. Both anti-Id were of equal efficacy in eliminating wild-type 38C13 cells by using 38C13 cells in tumor inoculums that had just been cloned in vitro, but MS11G6 was also capable of preventing the growth of several surface Ig+ variant cell lines in vivo. We conclude that anti-Id recognizing more stable Id determinants can limit the emergence of Id variants and therefore be more effective therapeutic agents. This finding is of additional importance as additional in vivo and immunophenotypic studies demonstrated that the generation of Id variants was an ongoing process both in cloned parental 38C13 cells and its variants.

摘要

Id 变体的出现是人类 B 细胞恶性肿瘤和小鼠 B 细胞淋巴瘤 38C13 逃避抗 Id 治疗的主要机制。为了确定抗 Id 抗体的表位特异性对预防 38C13 淋巴瘤中此类 Id 变体出现的影响,制备并研究了针对 38C13 肿瘤细胞 Id 具有不同表位特异性的抗 Id 单克隆抗体。一些通过用野生型 38C13 IgM 和变体 IgM 免疫小鼠产生的抗体,与野生型 38C13 IgM 以及一组变体 IgM 的所有四个成员发生交叉反应。这些抗 Id 通过 Western 印迹法不与分离的 38C13 IgM H 链或 L 链反应,但确实与表面 Ig 变体细胞系 T2D 的细胞质 H 链反应,该细胞系在其细胞质中表达与野生型 38C13 相同的 H 链,但不表达任何相关的 L 链。相比之下,特异性较窄的抗 Id 不与该 H 链反应。这表明广泛交叉反应的抗体识别 38C13 H 链上的一个稳定表位。当将广泛交叉反应的抗体 MS11G6 与特异性较窄的抗体 S1C5 进行比较时,MS11G6 在预防接种 38C∣3 细胞的小鼠肿瘤生长方面更具优势。此外,在 MS11G6 治疗组的逃逸肿瘤中未出现表面 Ig+变体,而在 S1C5 治疗组中此类变体很常见。在使用刚在体外克隆的肿瘤接种物中的 38C13 细胞消除野生型 38C13 细胞方面,两种抗 Id 的功效相同,但 MS11G6 也能够在体内预防几种表面 Ig+变体细胞系的生长。我们得出结论,识别更稳定 Id 决定簇的抗 Id 可以限制 Id 变体出现,因此是更有效的治疗剂。这一发现尤为重要,因为更多的体内和免疫表型研究表明,Id 变体的产生在克隆的亲本 38C13 细胞及其变体中都是一个持续的过程。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验